A second-generation Covid-19 vaccine developed by CureVac and GlaxoSmithKline – designed to protect against coronavirus variants – produced a high level of immune response in a trial in rats, the companies said on May 13.
Europe’s medicines regulator said on May 7 the EMA has begun a real-time review of the Covid-19 antibody treatment developed by GSK and Vir Biotechnology,, formally kicking off the process for a potential European Union approval.
The U.S. Food and Drug Administration approved GlaxoSmithKline’s new checkpoint inhibitor, Jemperli (dostarlimab), for patients with recurrent or advanced endometrial cancer.
The tenth annual Pharmaceutical Innovation Index, released April 21, sees Eli Lilly top the industry for the first time. The Pharmaceutical Invention Index, a ranking of the industry’s best pipelines, rated Bristol Myers Squibb as No. 1.
GlaxoSmithKline halted two mid-stage studies assessing feladilimab combined with Merck’s Keytruda as a potential treatment in different oncology settings.
GSK and Vir Biotechnology filed an application to U.S. regulators for emergency use authorization of their antibody therapy to treat early-stage Covid-19 infections, the drugmakers said on March 26.
Moncef Slaoui, who served as chief scientist for the Operation Warp Speed response to the Covid-19 pandemic under former President Donald Trump, was fired as chairman of the board of directors of Galvani Bioelectronics following the “substantiation” of allegations of sexual harassment and inappropriate conduct.
Medicago said on March 16 the Canadian drug developer had started a late-stage study of the company’s experimental Covid-19 vaccine combined with an adjuvant from GlaxoSmithKline.
Genentech reported that the company’s rheumatoid arthritis drug Actemra failed to hit the primary endpoint in a Covid-19 trial, while Vir and GlaxoSmithKline’s antibody against Covid-19 demonstrated 85 percent efficacy.
Vir Biotechnology and GlaxoSmithKline plan to seek emergency use authorization for their experimental Covid-19 antibody therapy after interim data from a study showed 85 percent reduction in hospitalization and deaths among patients.
